Skip to main content
. 2021 Feb 5;14:867–877. doi: 10.2147/OTT.S293163

Table 1.

Baseline Clinicopathological Data of Patients with HNSCC and Expression of p53 and TLR9 in Relation to HPV and p16 Status

HPV p16
Clinicopathological Variables n Positive (n=24) Negative (n=61) P value High (n=27) Low (n=58) P value
Age
 <60 40 (47.06%) 16 24 19 21
 >60 45 (52.94%) 8 37 0.023 8 37 0.003
Sex
 Male 69 (81.18%) 19 50 22 47
 Female 16 (18.82%) 5 11 0.766 5 11 0.961
Smoking history
 >10 pack-year 58 (68.24%) 12 46 14 44
 <10 pack-year 27 (31.76%) 12 15 0.024 13 14 0.027
Alcohol intake
 >3U/d 48 (56.47%) 10 38 11 37
 <3U/d 37 (43.53%) 14 23 0.084 16 21 0.046
T class
 T1-T2 41 (48.24%) 13 28 15 26
 T3-T4 44 (51.76%) 11 33 0.492 12 32 0.356
N class
 N0-N1 33 (38.82%) 5 28 6 27
 N2-N3 52 (61.18%) 19 33 0.033 21 31 0.032
Stage
 I–II 20 (23.53%) 4 16 5 15
 III–IV 65 (76.47%) 20 45 0.349 22 43 0.457
Tumor site
 Oropharynx 35 (41.18%) 18 17 20 15
 Larynx 30 (35.29%) 3 27 4 26
 Hypopharynx 14 (16.47%) 2 12 2 12
 Oral cavity 6 (7.06%) 1 5 0.001 1 5 0.001
Differentiation
 Well 18 (21.18%) 2 16 2 16
 Moderate 33 (38.82%) 6 27 8 25
 Poor 34 (40.00%) 16 18 0.006 17 17 0.008
Treatment
 Sx±(C)RT 51 (60%) 13 38 14 37
 (C)RT±Sx 34 (40%) 11 23 0.491 13 21 0.295
p53
 High 52 (61.18%) 3 49 5 47
 Low 33 (38.82%) 21 12 0.00 22 11 0.00
TLR 9
 High 42 (49.41%) 7 35 8 34
 Low 43 (50.59%) 17 26 0.019 19 24 0.013

Note: Significant results (P < 0.05) are given in bold.